The Centers for Medicare and Medicaid Services has launched a National Coverage Analysis (NCA) of sipuleucel-T (Provenge), a recently approved cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant prostate cancer. The agent is the first in a new therapeutic class known as autologous cellular immunotherapies.
The Centers for Medicare and Medicaid Services has launched a National Coverage Analysis (NCA) of sipuleucel-T (Provenge), a recently approved cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant prostate cancer. The agent is the first in a new therapeutic class known as autologous cellular immunotherapies.
CMS says it is opening this national coverage analysis to determine whether autologous cellular immunotherapy is reasonable and necessary under certain sections of the Social Security Act.
CMS is seeking public comment on the effects of sipuleucel-T on health outcomes in patients with prostate cancer. This does not reflect a change in Medicare coverage policy, according to Dendreon Corp., the drug’s manufacturer. NCAs do not affect existing coverage decisions, and they do not limit local Medicare contractors from covering sipuleucel-T, the company said. Medicare beneficiaries can still access sipuleucel-T and private payers can also still cover sipuleucel-T.
The initial 30-day public comment period began on June 30, 2010 and ends after 30 calendar days. CMS said it is "particularly interested in clinical studies and other scientific information relevant to the subject under review." Instructions on submitting public comments can be found at www.cms.hhs.gov/InfoExchange/02_publiccomments.asp.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.